$AERI Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in AERIE PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in AERIE PHARMACEUTICALS INC. Get notifications about new insider transactions in AERIE PHARMACEUTICALS INC for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Feb 25 2021 | AERI | AERIE PHARMACEUTIC ... | RUBINO RICHARD J | Chief Financial Off ... | Payment of Exercise | F | 15.66 | 410 | 6,421 | 353,937 | 354.3 K to 353.9 K (-0.12 %) |
Feb 25 2021 | AERI | AERIE PHARMACEUTIC ... | MITRO THOMAS A | President and COO | Payment of Exercise | F | 15.66 | 763 | 11,949 | 86,709 | 87.5 K to 86.7 K (-0.87 %) |
Feb 25 2021 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Payment of Exercise | F | 15.66 | 328 | 5,136 | 264,469 | 264.8 K to 264.5 K (-0.12 %) |
Feb 25 2021 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Payment of Exercise | F | 15.66 | 1,700 | 26,622 | 233,396 | 235.1 K to 233.4 K (-0.72 %) |
Feb 23 2021 | AERI | AERIE PHARMACEUTIC ... | LaRocca John | General Counsel | Payment of Exercise | F | 15.95 | 1,542 | 24,595 | 40,437 | 42 K to 40.4 K (-3.67 %) |
Feb 17 2021 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Option Exercise | M | 0.20 | 60,651 | 11,888 | 0 | |
Feb 17 2021 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Payment of Exercise | F | 16.41 | 725 | 11,897 | 264,797 | 265.5 K to 264.8 K (-0.27 %) |
Feb 17 2021 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Buy | M | 0.20 | 60,651 | 11,888 | 265,522 | 204.9 K to 265.5 K (+29.60 %) |
Feb 09 2021 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Payment of Exercise | F | 17.72 | 2,500 | 44,300 | 235,096 | 237.6 K to 235.1 K (-1.05 %) |
Feb 09 2021 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Payment of Exercise | F | 17.68 | 2,496 | 44,129 | 237,596 | 240.1 K to 237.6 K (-1.04 %) |
Feb 09 2021 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Payment of Exercise | F | 17.68 | 2,958 | 52,297 | 240,092 | 243.1 K to 240.1 K (-1.22 %) |
Feb 09 2021 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Payment of Exercise | F | 17.72 | 666 | 11,802 | 204,871 | 205.5 K to 204.9 K (-0.32 %) |
Feb 09 2021 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Payment of Exercise | F | 17.68 | 701 | 12,394 | 205,537 | 206.2 K to 205.5 K (-0.34 %) |
Feb 09 2021 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Payment of Exercise | F | 17.68 | 876 | 15,488 | 206,238 | 207.1 K to 206.2 K (-0.42 %) |
Feb 09 2021 | AERI | AERIE PHARMACEUTIC ... | LaRocca John | General Counsel | Payment of Exercise | F | 17.68 | 706 | 12,482 | 41,979 | 42.7 K to 42 K (-1.65 %) |
Feb 09 2021 | AERI | AERIE PHARMACEUTIC ... | LaRocca John | General Counsel | Payment of Exercise | F | 17.68 | 353 | 6,241 | 42,685 | 43 K to 42.7 K (-0.82 %) |
Feb 09 2021 | AERI | AERIE PHARMACEUTIC ... | MITRO THOMAS A | President and COO | Payment of Exercise | F | 17.72 | 1,085 | 19,226 | 87,472 | 88.6 K to 87.5 K (-1.23 %) |
Feb 09 2021 | AERI | AERIE PHARMACEUTIC ... | MITRO THOMAS A | President and COO | Payment of Exercise | F | 17.68 | 1,229 | 21,729 | 88,557 | 89.8 K to 88.6 K (-1.37 %) |
Feb 09 2021 | AERI | AERIE PHARMACEUTIC ... | MITRO THOMAS A | President and COO | Payment of Exercise | F | 17.68 | 1,438 | 25,424 | 89,786 | 91.2 K to 89.8 K (-1.58 %) |
Feb 09 2021 | AERI | AERIE PHARMACEUTIC ... | RUBINO RICHARD J | Chief Financial Off ... | Payment of Exercise | F | 17.72 | 921 | 16,320 | 354,347 | 355.3 K to 354.3 K (-0.26 %) |
Feb 09 2021 | AERI | AERIE PHARMACEUTIC ... | RUBINO RICHARD J | Chief Financial Off ... | Payment of Exercise | F | 17.68 | 1,075 | 19,006 | 355,268 | 356.3 K to 355.3 K (-0.30 %) |
Feb 09 2021 | AERI | AERIE PHARMACEUTIC ... | RUBINO RICHARD J | Chief Financial Off ... | Payment of Exercise | F | 17.68 | 1,185 | 20,951 | 356,343 | 357.5 K to 356.3 K (-0.33 %) |
Feb 08 2021 | AERI | AERIE PHARMACEUTIC ... | Hollander David | Chief R&D Officer | Option Exercise | A | 17.64 | 50,000 | 882,000 | 50,000 | |
Feb 08 2021 | AERI | AERIE PHARMACEUTIC ... | Hollander David | Chief R&D Officer | Grant | A | 0.00 | 11,000 | 0 | 33,838 | 22.8 K to 33.8 K (+48.17 %) |
Feb 08 2021 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Option Exercise | A | 17.64 | 50,000 | 882,000 | 50,000 | |
Feb 08 2021 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Grant | A | 0.00 | 11,000 | 0 | 207,114 | 196.1 K to 207.1 K (+5.61 %) |
Feb 08 2021 | AERI | AERIE PHARMACEUTIC ... | LaRocca John | General Counsel | Option Exercise | A | 17.64 | 50,000 | 882,000 | 50,000 | |
Feb 08 2021 | AERI | AERIE PHARMACEUTIC ... | LaRocca John | General Counsel | Grant | A | 0.00 | 11,000 | 0 | 43,038 | 32 K to 43 K (+34.33 %) |
Feb 08 2021 | AERI | AERIE PHARMACEUTIC ... | MITRO THOMAS A | President and COO | Option Exercise | A | 17.64 | 62,500 | 1,102,500 | 62,500 | |
Feb 08 2021 | AERI | AERIE PHARMACEUTIC ... | MITRO THOMAS A | President and COO | Grant | A | 0.00 | 14,000 | 0 | 91,224 | 77.2 K to 91.2 K (+18.13 %) |
Feb 08 2021 | AERI | AERIE PHARMACEUTIC ... | RUBINO RICHARD J | Chief Financial Off ... | Option Exercise | A | 17.64 | 52,000 | 917,280 | 52,000 | |
Feb 08 2021 | AERI | AERIE PHARMACEUTIC ... | RUBINO RICHARD J | Chief Financial Off ... | Grant | A | 0.00 | 12,000 | 0 | 357,528 | 345.5 K to 357.5 K (+3.47 %) |
Feb 08 2021 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Option Exercise | A | 17.64 | 125,000 | 2,205,000 | 125,000 | |
Feb 08 2021 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Grant | A | 0.00 | 28,000 | 0 | 243,050 | 215.1 K to 243.1 K (+13.02 %) |
Nov 12 2020 | AERI | AERIE PHARMACEUTIC ... | Hollander David | Chief R&D Officer | Payment of Exercise | F | 13.05 | 2,162 | 28,214 | 22,838 | 25 K to 22.8 K (-8.65 %) |
Nov 12 2020 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Sell | S | 13.01 | 22,695 | 295,210 | 196,114 | 218.8 K to 196.1 K (-10.37 %) |
Nov 12 2020 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Sell | S | 13.00 | 7,305 | 94,965 | 218,809 | 226.1 K to 218.8 K (-3.23 %) |
Aug 18 2020 | AERI | AERIE PHARMACEUTIC ... | LaRocca John | General Counsel | Payment of Exercise | F | 12.71 | 685 | 8,706 | 32,038 | 32.7 K to 32 K (-2.09 %) |
Jun 29 2020 | AERI | AERIE PHARMACEUTIC ... | Cagle Gerald D. | Director | Option Exercise | A | 13.27 | 7,800 | 103,506 | 7,800 | |
Jun 29 2020 | AERI | AERIE PHARMACEUTIC ... | Cagle Gerald D. | Director | Grant | A | 0.00 | 1,750 | 0 | 18,300 | 16.6 K to 18.3 K (+10.57 %) |
Jun 29 2020 | AERI | AERIE PHARMACEUTIC ... | Croarkin Richard | Director | Option Exercise | A | 13.27 | 7,800 | 103,506 | 7,800 | |
Jun 29 2020 | AERI | AERIE PHARMACEUTIC ... | Croarkin Richard | Director | Grant | A | 0.00 | 1,750 | 0 | 8,100 | 6.4 K to 8.1 K (+27.56 %) |
Jun 29 2020 | AERI | AERIE PHARMACEUTIC ... | du Toit Michael | Director | Option Exercise | A | 13.27 | 7,800 | 103,506 | 7,800 | |
Jun 29 2020 | AERI | AERIE PHARMACEUTIC ... | du Toit Michael | Director | Grant | A | 0.00 | 1,750 | 0 | 8,100 | 6.4 K to 8.1 K (+27.56 %) |
Jun 29 2020 | AERI | AERIE PHARMACEUTIC ... | GRYSKA DAVID W | Director | Option Exercise | A | 13.27 | 7,800 | 103,506 | 7,800 | |
Jun 29 2020 | AERI | AERIE PHARMACEUTIC ... | GRYSKA DAVID W | Director | Grant | A | 0.00 | 1,750 | 0 | 3,500 | 1.8 K to 3.5 K (+100.00 %) |
Jun 29 2020 | AERI | AERIE PHARMACEUTIC ... | MCGRAW BENJAMIN F III | Director | Option Exercise | A | 13.27 | 7,800 | 103,506 | 7,800 | |
Jun 29 2020 | AERI | AERIE PHARMACEUTIC ... | MCGRAW BENJAMIN F III | Director | Grant | A | 0.00 | 1,750 | 0 | 9,800 | 8.1 K to 9.8 K (+21.74 %) |
Jun 29 2020 | AERI | AERIE PHARMACEUTIC ... | McHugh Julie | Director | Option Exercise | A | 13.27 | 7,800 | 103,506 | 7,800 | |
Jun 29 2020 | AERI | AERIE PHARMACEUTIC ... | McHugh Julie | Director | Grant | A | 0.00 | 1,750 | 0 | 8,100 | 6.4 K to 8.1 K (+27.56 %) |
Jun 11 2020 | AERI | AERIE PHARMACEUTIC ... | McDonnell Peter J | Director | Option Exercise | A | 15.30 | 25,000 | 382,500 | 25,000 | |
May 20 2020 | AERI | AERIE PHARMACEUTIC ... | GOLDBERG MURRAY A | Director | Option Exercise | M | 3.15 | 28,000 | 88,200 | 0 | |
May 20 2020 | AERI | AERIE PHARMACEUTIC ... | GOLDBERG MURRAY A | Director | Buy | M | 3.15 | 28,000 | 88,200 | 36,050 | 8.1 K to 36.1 K (+347.83 %) |
May 18 2020 | AERI | AERIE PHARMACEUTIC ... | RUBINO RICHARD J | Chief Financial Off ... | Payment of Exercise | F | 14.85 | 2,323 | 34,485 | 345,528 | 347.9 K to 345.5 K (-0.67 %) |
May 18 2020 | AERI | AERIE PHARMACEUTIC ... | MITRO THOMAS A | President and COO | Payment of Exercise | F | 14.85 | 2,345 | 34,812 | 77,224 | 79.6 K to 77.2 K (-2.95 %) |
May 18 2020 | AERI | AERIE PHARMACEUTIC ... | RUBINO RICHARD J | Chief Financial Off ... | Payment of Exercise | F | 14.85 | 2,323 | 34,485 | 345,528 | 347.9 K to 345.5 K (-0.67 %) |
May 18 2020 | AERI | AERIE PHARMACEUTIC ... | MITRO THOMAS A | President and COO | Payment of Exercise | F | 14.85 | 2,345 | 34,812 | 77,224 | 79.6 K to 77.2 K (-2.95 %) |
May 18 2020 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Payment of Exercise | F | 14.85 | 4,746 | 70,454 | 215,050 | 219.8 K to 215.1 K (-2.16 %) |
May 12 2020 | AERI | AERIE PHARMACEUTIC ... | Cagle Gerald D. | Director | Sell | S | 15.27 | 5,000 | 76,350 | 16,550 | 21.6 K to 16.6 K (-23.20 %) |
Mar 02 2020 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Sell | S | 17.07 | 271,767 | 4,639,063 | 1,229,633 | 1.5 M to 1.2 M (-18.10 %) |
Mar 02 2020 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Sell | S | 17.07 | 425,457 | 7,262,551 | 1,925,020 | 2.4 M to 1.9 M (-18.10 %) |
Mar 02 2020 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Sell | S | 17.07 | 302,776 | 5,168,386 | 1,369,938 | 1.7 M to 1.4 M (-18.10 %) |
Feb 25 2020 | AERI | AERIE PHARMACEUTIC ... | RUBINO RICHARD J | Chief Financial Off ... | Payment of Exercise | F | 20.30 | 857 | 17,397 | 347,851 | 348.7 K to 347.9 K (-0.25 %) |
Feb 25 2020 | AERI | AERIE PHARMACEUTIC ... | RUBINO RICHARD J | Chief Financial Off ... | Payment of Exercise | F | 21.59 | 410 | 8,852 | 348,708 | 349.1 K to 348.7 K (-0.12 %) |
Feb 25 2020 | AERI | AERIE PHARMACEUTIC ... | MITRO THOMAS A | President and COO | Payment of Exercise | F | 20.30 | 1,027 | 20,848 | 79,569 | 80.6 K to 79.6 K (-1.27 %) |
Feb 25 2020 | AERI | AERIE PHARMACEUTIC ... | MITRO THOMAS A | President and COO | Payment of Exercise | F | 21.59 | 763 | 16,473 | 80,596 | 81.4 K to 80.6 K (-0.94 %) |
Feb 25 2020 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Payment of Exercise | F | 20.30 | 1,527 | 30,998 | 219,796 | 221.3 K to 219.8 K (-0.69 %) |
Feb 25 2020 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Payment of Exercise | F | 21.59 | 1,052 | 22,713 | 221,323 | 222.4 K to 221.3 K (-0.47 %) |
Feb 21 2020 | AERI | AERIE PHARMACEUTIC ... | LaRocca John | General Counsel | Payment of Exercise | F | 19.47 | 1,542 | 30,023 | 32,723 | 34.3 K to 32.7 K (-4.50 %) |
Feb 11 2020 | AERI | AERIE PHARMACEUTIC ... | RUBINO RICHARD J | Chief Financial Off ... | Payment of Exercise | F | 20.49 | 1,023 | 20,961 | 349,118 | 350.1 K to 349.1 K (-0.29 %) |
Feb 11 2020 | AERI | AERIE PHARMACEUTIC ... | RUBINO RICHARD J | Chief Financial Off ... | Payment of Exercise | F | 20.49 | 1,055 | 21,617 | 350,141 | 351.2 K to 350.1 K (-0.30 %) |
Feb 11 2020 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Payment of Exercise | F | 20.49 | 1,546 | 31,678 | 222,375 | 223.9 K to 222.4 K (-0.69 %) |
Feb 11 2020 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Payment of Exercise | F | 20.49 | 1,710 | 35,038 | 223,921 | 225.6 K to 223.9 K (-0.76 %) |
Feb 11 2020 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Payment of Exercise | F | 20.49 | 700 | 14,343 | 227,111 | 227.8 K to 227.1 K (-0.31 %) |
Feb 11 2020 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Payment of Exercise | F | 20.49 | 700 | 14,343 | 227,811 | 228.5 K to 227.8 K (-0.31 %) |
Feb 11 2020 | AERI | AERIE PHARMACEUTIC ... | LaRocca John | General Counsel | Payment of Exercise | F | 20.49 | 693 | 14,200 | 34,265 | 35 K to 34.3 K (-1.98 %) |
Feb 11 2020 | AERI | AERIE PHARMACEUTIC ... | MITRO THOMAS A | President and COO | Payment of Exercise | F | 20.49 | 1,183 | 24,240 | 81,359 | 82.5 K to 81.4 K (-1.43 %) |
Feb 11 2020 | AERI | AERIE PHARMACEUTIC ... | MITRO THOMAS A | President and COO | Payment of Exercise | F | 20.49 | 1,307 | 26,780 | 82,542 | 83.8 K to 82.5 K (-1.56 %) |
Feb 10 2020 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Option Exercise | A | 21.18 | 45,000 | 953,100 | 45,000 | |
Feb 10 2020 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Grant | A | 0.00 | 10,000 | 0 | 228,511 | 218.5 K to 228.5 K (+4.58 %) |
Feb 10 2020 | AERI | AERIE PHARMACEUTIC ... | RUBINO RICHARD J | Chief Financial Off ... | Option Exercise | A | 21.18 | 52,000 | 1,101,360 | 52,000 | |
Feb 10 2020 | AERI | AERIE PHARMACEUTIC ... | RUBINO RICHARD J | Chief Financial Off ... | Grant | A | 0.00 | 11,750 | 0 | 351,196 | 339.4 K to 351.2 K (+3.46 %) |
Feb 10 2020 | AERI | AERIE PHARMACEUTIC ... | LaRocca John | General Counsel | Option Exercise | A | 21.18 | 15,500 | 328,290 | 15,500 | |
Feb 10 2020 | AERI | AERIE PHARMACEUTIC ... | LaRocca John | General Counsel | Grant | A | 0.00 | 3,500 | 0 | 34,958 | 31.5 K to 35 K (+11.13 %) |
Feb 10 2020 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Option Exercise | A | 21.18 | 125,000 | 2,647,500 | 125,000 | |
Feb 10 2020 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Grant | A | 0.00 | 28,000 | 0 | 225,631 | 197.6 K to 225.6 K (+14.17 %) |
Feb 10 2020 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Buy | W | 0.00 | 2,250 | 0 | 10,500 | 8.3 K to 10.5 K (+27.27 %) |
Feb 10 2020 | AERI | AERIE PHARMACEUTIC ... | MITRO THOMAS A | President and COO | Option Exercise | A | 21.18 | 62,500 | 1,323,750 | 62,500 | |
Feb 10 2020 | AERI | AERIE PHARMACEUTIC ... | MITRO THOMAS A | President and COO | Grant | A | 0.00 | 14,000 | 0 | 83,849 | 69.8 K to 83.8 K (+20.04 %) |
Dec 23 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management IV ... | 10% Owner | Option Exercise | X | 30.00 | 289 | 8,670 | 0 | |
Dec 23 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management IV ... | 10% Owner | Buy | X | 30.00 | 28,900 | 867,000 | 1,501,400 | 1.5 M to 1.5 M (+1.96 %) |
Dec 05 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management IV ... | 10% Owner | Option Exercise | X | 30.00 | 266 | 7,980 | 289 | |
Dec 05 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management IV ... | 10% Owner | Option Exercise | X | 30.00 | 44 | 1,320 | 555 | |
Dec 05 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management IV ... | 10% Owner | Buy | X | 30.00 | 26,600 | 798,000 | 1,472,500 | 1.4 M to 1.5 M (+1.84 %) |
Dec 05 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management IV ... | 10% Owner | Buy | X | 30.00 | 4,400 | 132,000 | 1,445,900 | 1.4 M to 1.4 M (+0.31 %) |
Dec 05 2019 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Option Exercise | M | 0.41 | 117,000 | 47,385 | 0 | |
Dec 05 2019 | AERI | AERIE PHARMACEUTIC ... | Kopczynski Casey C. | Chief Scientific Of ... | Buy | M | 0.41 | 117,000 | 47,385 | 218,511 | 101.5 K to 218.5 K (+115.26 %) |
Nov 18 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management IV ... | 10% Owner | Option Exercise | X | 30.00 | 199 | 5,970 | 599 | |
Nov 18 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management IV ... | 10% Owner | Option Exercise | X | 30.00 | 57 | 1,710 | 798 | |
Nov 18 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management IV ... | 10% Owner | Buy | X | 30.00 | 19,900 | 597,000 | 1,441,500 | 1.4 M to 1.4 M (+1.40 %) |
Nov 18 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management IV ... | 10% Owner | Buy | X | 30.00 | 5,700 | 171,000 | 1,421,600 | 1.4 M to 1.4 M (+0.40 %) |
Nov 13 2019 | AERI | AERIE PHARMACEUTIC ... | Hollander David | Chief R&D Officer | Option Exercise | A | 19.05 | 110,000 | 2,095,500 | 110,000 | |
Nov 13 2019 | AERI | AERIE PHARMACEUTIC ... | Hollander David | Chief R&D Officer | Grant | A | 0.00 | 25,000 | 0 | 25,000 | 0 to 25 K |
Nov 12 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management IV ... | 10% Owner | Option Exercise | X | 30.00 | 150 | 4,500 | 855 | |
Nov 12 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management IV ... | 10% Owner | Buy | X | 30.00 | 15,000 | 450,000 | 1,415,900 | 1.4 M to 1.4 M (+1.07 %) |
Sep 09 2019 | AERI | AERIE PHARMACEUTIC ... | RUBINO RICHARD J | Chief Financial Off ... | Buy | P | 19.93 | 5,040 | 100,447 | 339,446 | 334.4 K to 339.4 K (+1.51 %) |
Sep 09 2019 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Buy | P | 19.95 | 2,000 | 39,900 | 197,631 | 195.6 K to 197.6 K (+1.02 %) |
Sep 09 2019 | AERI | AERIE PHARMACEUTIC ... | ANIDO VICENTE JR | Chief Executive Off ... | Buy | P | 18.93 | 24,250 | 459,053 | 195,631 | 171.4 K to 195.6 K (+14.15 %) |
Sep 06 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 18.42 | 15,700 | 289,194 | 2,350,477 | 2.3 M to 2.4 M (+0.67 %) |
Sep 06 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 18.42 | 15,700 | 289,194 | 2,350,477 | 2.3 M to 2.4 M (+0.67 %) |
Sep 06 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 18.48 | 90,900 | 1,679,832 | 1,400,900 | 1.3 M to 1.4 M (+6.94 %) |
Sep 06 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 18.48 | 90,900 | 1,679,832 | 1,400,900 | 1.3 M to 1.4 M (+6.94 %) |
Sep 06 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 18.48 | 9,300 | 171,864 | 2,334,777 | 2.3 M to 2.3 M (+0.40 %) |
Sep 06 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 18.48 | 9,300 | 171,864 | 2,334,777 | 2.3 M to 2.3 M (+0.40 %) |
Sep 04 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 21.45 | 15,100 | 323,895 | 2,325,477 | 2.3 M to 2.3 M (+0.65 %) |
Sep 04 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 20.54 | 34,900 | 716,846 | 2,310,377 | 2.3 M to 2.3 M (+1.53 %) |
Sep 04 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 21.36 | 25,000 | 534,000 | 2,275,477 | 2.3 M to 2.3 M (+1.11 %) |
Aug 23 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 23.42 | 38,300 | 896,986 | 2,250,477 | 2.2 M to 2.3 M (+1.73 %) |
Aug 23 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 23.68 | 6,700 | 158,656 | 2,212,177 | 2.2 M to 2.2 M (+0.30 %) |
Aug 23 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 23.42 | 38,300 | 896,986 | 2,250,477 | 2.2 M to 2.3 M (+1.73 %) |
Aug 23 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 23.25 | 1,153 | 26,807 | 2,205,477 | 2.2 M to 2.2 M (+0.05 %) |
Aug 23 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 23.68 | 6,700 | 158,656 | 2,212,177 | 2.2 M to 2.2 M (+0.30 %) |
Aug 23 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 23.25 | 1,153 | 26,807 | 2,205,477 | 2.2 M to 2.2 M (+0.05 %) |
Aug 20 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 23.21 | 50,000 | 1,160,500 | 2,204,324 | 2.2 M to 2.2 M (+2.32 %) |
Aug 20 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 23.34 | 3,847 | 89,789 | 2,154,324 | 2.2 M to 2.2 M (+0.18 %) |
Aug 20 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 24.23 | 100,000 | 2,423,000 | 2,150,477 | 2.1 M to 2.2 M (+4.88 %) |
Aug 20 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 23.21 | 50,000 | 1,160,500 | 2,204,324 | 2.2 M to 2.2 M (+2.32 %) |
Aug 20 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 23.34 | 3,847 | 89,789 | 2,154,324 | 2.2 M to 2.2 M (+0.18 %) |
Aug 20 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 24.23 | 100,000 | 2,423,000 | 2,150,477 | 2.1 M to 2.2 M (+4.88 %) |
Aug 16 2019 | AERI | AERIE PHARMACEUTIC ... | LaRocca John | General Counsel | Option Exercise | A | 23.97 | 36,000 | 862,920 | 36,000 | |
Aug 16 2019 | AERI | AERIE PHARMACEUTIC ... | LaRocca John | General Counsel | Grant | A | 0.00 | 8,000 | 0 | 31,458 | 23.5 K to 31.5 K (+34.10 %) |
Aug 14 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 23.73 | 100,000 | 2,373,000 | 2,050,477 | 2 M to 2.1 M (+5.13 %) |
Aug 14 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 25.52 | 178,903 | 4,565,605 | 1,310,000 | 1.1 M to 1.3 M (+15.82 %) |
Aug 14 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 24.92 | 71,097 | 1,771,737 | 1,131,097 | 1.1 M to 1.1 M (+6.71 %) |
Aug 14 2019 | AERI | AERIE PHARMACEUTIC ... | Foresite Capital Management II ... | 10% Owner | Buy | P | 24.43 | 189,555 | 4,630,829 | 1,060,000 | 870.4 K to 1.1 M (+21.78 %) |
May 24 2019 | AERI | AERIE PHARMACEUTIC ... | GOLDBERG MURRAY A | Director | Option Exercise | A | 39.44 | 7,800 | 307,632 | 7,800 | |
May 24 2019 | AERI | AERIE PHARMACEUTIC ... | GOLDBERG MURRAY A | Director | Grant | A | 0.00 | 1,750 | 0 | 8,050 | 6.3 K to 8.1 K (+27.78 %) |
May 23 2019 | AERI | AERIE PHARMACEUTIC ... | McHugh Julie | Director | Option Exercise | A | 39.44 | 7,800 | 307,632 | 7,800 | |
May 23 2019 | AERI | AERIE PHARMACEUTIC ... | McHugh Julie | Director | Grant | A | 0.00 | 1,750 | 0 | 6,350 | 4.6 K to 6.4 K (+38.04 %) |
May 23 2019 | AERI | AERIE PHARMACEUTIC ... | MCGRAW BENJAMIN F III | Director | Option Exercise | A | 39.44 | 7,800 | 307,632 | 7,800 | |
May 23 2019 | AERI | AERIE PHARMACEUTIC ... | MCGRAW BENJAMIN F III | Director | Grant | A | 0.00 | 1,750 | 0 | 8,050 | 6.3 K to 8.1 K (+27.78 %) |
May 23 2019 | AERI | AERIE PHARMACEUTIC ... | GRYSKA DAVID W | Director | Option Exercise | A | 39.44 | 7,800 | 307,632 | 7,800 | |
May 23 2019 | AERI | AERIE PHARMACEUTIC ... | GRYSKA DAVID W | Director | Grant | A | 0.00 | 1,750 | 0 | 1,750 | 0 to 1.8 K |
May 23 2019 | AERI | AERIE PHARMACEUTIC ... | du Toit Michael | Director | Option Exercise | A | 39.44 | 7,800 | 307,632 | 7,800 | |
May 23 2019 | AERI | AERIE PHARMACEUTIC ... | du Toit Michael | Director | Grant | A | 0.00 | 1,750 | 0 | 6,350 | 4.6 K to 6.4 K (+38.04 %) |
May 23 2019 | AERI | AERIE PHARMACEUTIC ... | Croarkin Richard | Director | Option Exercise | A | 39.44 | 7,800 | 307,632 | 7,800 | |
May 23 2019 | AERI | AERIE PHARMACEUTIC ... | Croarkin Richard | Director | Grant | A | 0.00 | 1,750 | 0 | 6,350 | 4.6 K to 6.4 K (+38.04 %) |
May 23 2019 | AERI | AERIE PHARMACEUTIC ... | Cagle Gerald D. | Director | Option Exercise | A | 39.44 | 7,800 | 307,632 | 7,800 | |
May 23 2019 | AERI | AERIE PHARMACEUTIC ... | Cagle Gerald D. | Director | Grant | A | 0.00 | 1,750 | 0 | 21,550 | 19.8 K to 21.6 K (+8.84 %) |
May 17 2019 | AERI | AERIE PHARMACEUTIC ... | MITRO THOMAS A | President and COO | Payment of Exercise | F | 40.54 | 2,345 | 95,066 | 69,849 | 72.2 K to 69.8 K (-3.25 %) |